This New Zepbound Study Could Be Great News for Eli Lilly Investors

Real-world study results suggest Zepbound users over 55 incur up to 15% lower healthcare costs at six months and up to 38% lower costs at one year versus similar patients not on the drug, with lower hospital admissions and ER visits. While the study excluded Zepbound drug costs (a key caveat), the findings could support expanded third-party insurance coverage and potentially increase demand. Separately, Eli Lilly reported Q2 revenue up 48% YoY to $23B, with Zepbound revenue up 46% YoY to $4.9B and Mounjaro up 91% to $9.9B.

Analysis

The key mechanism is not the study itself but what it changes in payer negotiation power. If Lilly can show lower downstream utilization in an older, comorbidity-heavy population, the first-order benefit is improved formulary access and lower friction at renewal cycles; the second-order benefit is conversion of cash-pay demand into reimbursed demand, which is a much larger volume unlock than any incremental price action. That said, insurers will discount any analysis that excludes drug cost, so this is more useful as a sales tool than as definitive actuarial proof.

The biggest losers are the cash-pay ecosystem and compounded-GLP-1 channels, because broader coverage reduces the arbitrage that has diverted patients away from branded products. In a stronger coverage regime, Lilly’s mix should improve through persistence and adherence, but gross-to-net could worsen if access is won via rebates or stricter preferred positioning. Near term, the stock may not rerate materially; the real catalyst window is 1-3 months around employer plan updates and PBM formulary decisions, with the structural upside showing up over 6-18 months if volume growth outpaces rebate leakage.

The market may be underestimating how little it takes for demand to re-accelerate once the out-of-pocket hurdle drops, especially in a category where willingness to pay is highly elastic. The contrarian risk is that payers respond by tightening prior auth or step edits rather than broadening coverage, which would preserve Lilly’s pricing power but mute unit growth. Falsifier: if management commentary over the next two quarters shows no improvement in covered lives, or if gross-to-net expands without a corresponding acceleration in Zepbound scripts, the thesis is delayed rather than validated.

Key Decisions for Investors

• Add LLY on weakness, not strength: initiate or scale only on a 3-5% pullback, with a 3-6 month horizon. Risk/reward favors upside if payer access improves, but the near-term catalyst is soft and headline-driven.
• Pair trade: long LLY / short NVO for 1-3 months if coverage headlines start favoring Lilly formulary positioning. Thesis: incremental script share should accrue to the company with the stronger access narrative, while the short caps downside if the class expands unevenly.
• Watchlist, not trade: compounded-GLP-1 exposure via telehealth/compounding sellers should be sold on any formal coverage expansion signal. The risk is a demand migration back to branded channels, but confirm with script data before shorting anything directly.
• Set a falsification trigger: if covered-life commentary does not improve by the next PBM/employer renewal cycle, treat this as a sentiment-positive but earnings-neutral event and fade chase buying in LLY.